Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma

Timothy J. Voorhees, Anne W. Beaven, Christopher Dittus, George E Hucks, J. Kaitlin Morrison, Catherine Joyce Arago Cheng, Tammy Cavallo, Steven I. Park, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo, Natalie S. Grover

Blood (2022) 140 (Supplement 1): 12723–12724.

https://doi.org/10.1182/blood-2022-156660

Published: 2022

Journal Articles

Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie S. Grover, Paul M. Armistead, James M. Coghill, Jr., Katarzyna Joanna Jamieson, Robert Hagan, J. Kaitlin Morrison, Faith Brianne Buchanan, Catherine Joyce Arago Cheng, Anastasia Ivanova, Tammy Cavallo, John West, Megan Gonzalez, Jonathan S. Serody, Gianpietro Dotti

Blood (2022) 140 (Supplement 1): 7437–7438.

https://doi.org/10.1182/blood-2022-165558

Published: 2022

Journal Articles

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

George E. Hucks, Jr., Barbara Savoldo, Gianpietro Dotti, Catherine Joyce Arago Cheng, Caroline Babinec, Kimberly A. Kasow, Michael Winstead, Arpita Patel, Cammie Presler, Natalie S Grover, J. Kaitlin Morrison, Anne W. Beaven, Marcie L. Riches, Thomas C. Shea, Jonathan S. Serody

Blood (2021) 138 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2021-153968

Published: 2021

Journal Articles

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

Natalie S Grover, Anastasia Ivanova, Dominic T. Moore, Catherine Joyce Arago Cheng, Caroline Babinec, John West, Tammy Cavallo, J. Kaitlin Morrison, Faith Brianne Buchanan, Edith Bowers, Christopher Dittus, Anne W. Beaven, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo

Blood (2021) 138 (Supplement 1): 742.

https://doi.org/10.1182/blood-2021-148102

Published: 2021

Journal Articles

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie Grover, Paul Armistead, James Coghill, Robert S. Hagan, Kaitlin Morrison, Faith Brianne Buchanan, Catherine Cheng, Spencer Laing, Anastasia Ivanova, John West, Aaron Foster, Jonathan Serody, Gianpietro Dotti

Blood (2021) 137 (23): 3306–3309.

https://doi.org/10.1182/blood.2021010784

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)

Matthew C Foster, MD, Philip A. Roehrs, MD, George E Hucks, MD, Natalie S Grover, MD, Paul M. Armistead, MD PhD, Katarzyna Jamieson, MD, Faith Brianne Buchanan, PA, J. Kaitlin C Morrison, PhD, Spencer Laing, BA, Catherine Joyce Arago Cheng, BS, Jonathan S. Serody, MD, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139051

Published: 2020

Journal Articles

Novel Immunotherapeutic Approaches for Hodgkin Lymphoma

Barbara Savoldo, MD PhD, Natalie S Grover, MD, Carlos A. Ramos, MD, Gianpietro Dotti, MD

Blood (2019) 134 (Supplement_1): SCI-9.

https://doi.org/10.1182/blood-2019-121075

Published: 2019

Journal Articles

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Timothy J Voorhees, MD, Natalie S Grover, MD, Anne Beaven, MD, Steven I Park, MD, J. Kaitlin Morrison, PhD, Catherine Joyce Arago Cheng, BS, Spencer Laing, BA, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 3233.

https://doi.org/10.1182/blood-2019-122846

Published: 2019

Journal Articles

Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia

Eben Lichtman, MD, Hongwei Du, PhD, Barbara Savoldo, MD PhD, Soldano Ferrone, MD PhD, Guangming Li, PhD, Lishan Su, PhD, Gianpietro Dotti, MD

Blood (2018) 132 (Supplement 1): 701.

https://doi.org/10.1182/blood-2018-99-113468

Published: 2018

Journal Articles

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

Blood (2018) 132 (Supplement 1): 681.

https://doi.org/10.1182/blood-2018-99-113534

Published: 2018

Journal Articles

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Carlos A. Ramos, MD, Mrinalini Bilgi, Claudia P. Gerken, Olga Dakhova, Zhuyong Mei, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Cliona M. Rooney, PhD, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Helen E. Heslop, MDDSc, Malcolm K. Brenner, MD PhD

Blood (2018) 132 (Supplement 1): 680.

https://doi.org/10.1182/blood-2018-99-111202

Published: 2018

Journal Articles

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling

Diogo Gomes da Silva, Malini Mukherjee, Madhuwanti Srinivasan, Olga Dakhova, PhD, Hao Liu, PhD, Bambi Grilley, Adrian P. Gee, PhD, Sattva S. Neelapu, MD, Cliona M. Rooney, PhD, Helen E Heslop, MD DSc (Hon), Barbara Savoldo, MD PhD, Gianpietro Dotti, MD, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD, Carlos A. Ramos, MD

Blood (2016) 128 (22): 1851.

https://doi.org/10.1182/blood.V128.22.1851.1851

Published: 2016

Journal Articles

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies

Chuang Sun, Gianpietro Dotti, Barbara Savoldo

Blood (2016) 127 (26): 3350–3359.

https://doi.org/10.1182/blood-2015-12-629089

Published: 2016

Journal Articles

Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity

Enli Liu, MD MS, Yijiu Tong, Gianpietro Dotti, MD, Barbara Savoldo, MD, Muharrem Muftuoglu, Kayo Kondo, PhD, Malini Mukherjee, Jordan S. Orange, MD PhD, Catherine Sobieski, Abdullah Alsuliman, Hila Shaim, MD, Nobuhiko Imahashi, MD PhD, Michael J. Keating, MD, Chitra M. Hosing, MD, Nina Shah, MD, William Wierda, MD PhD, Richard Champlin, MD, Elizabeth J. Shpall, MD, Katayoun Rezvani, MDPhD

Blood (2015) 126 (23): 3091.

https://doi.org/10.1182/blood.V126.23.3091.3091

Published: 2015

Journal Articles

Safety of Multiple Doses of CAR T Cells

Rayne H. Rouce, MD, Kristen Fousek, Nabil Ahmed, MD, Stephen Gottschalk, MD, Barbara Savoldo, MD, Gianpietro Dotti, MD, Carlos A. Ramos, MD, Chrystal Louis, MD, Cliona M. Rooney, PhD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD

Blood (2015) 126 (23): 4425.

https://doi.org/10.1182/blood.V126.23.4425.4425

Published: 2015

Journal Articles

Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I/IIa Trial

Gunilla Enblad, MDPhD, Hannah Karlsson, PhD, Kristina Wikstrom, PhD, Magnus Essand, PhD, Barbara Savoldo, MD PhD, Malcolm K. Brenner, MD PhD, Gianpietro Dotti, MD, Helene Hallbook, MDPhD, Martin Hoglund, MD PhD, Hans Hagberg, MD PhD, Angelica Loskog, PhD

Blood (2015) 126 (23): 1534.

https://doi.org/10.1182/blood.V126.23.1534.1534

Published: 2015

Journal Articles

Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas

Carlos A. Ramos, MD, Brandon Ballard, BS, Enli Liu, MD MS, Olga Dakhova, PhD, Zhuyong Mei, MD, Hao Liu, PhD, Bambi Grilley, RPh, Cliona M. Rooney, PhD, Adrian P. Gee, PhD, Bill H. Chang, MD PhD, Catherine M. Bollard, MD, Malcolm K. Brenner, MD PhD, Gianpietro Dotti, MD, Helen E. Heslop, MD, Barbara Savoldo, MD PhD

Blood (2015) 126 (23): 185.

https://doi.org/10.1182/blood.V126.23.185.185

Published: 2015

Journal Articles

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

Xiaoou Zhou, Gianpietro Dotti, Robert A. Krance, Caridad A. Martinez, Swati Naik, Rammurti T. Kamble, April G. Durett, Olga Dakhova, Barbara Savoldo, Antonio Di Stasi, David M. Spencer, Yu-Feng Lin, Hao Liu, Bambi J. Grilley, Adrian P. Gee, Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner

Blood (2015) 125 (26): 4103–4113.

https://doi.org/10.1182/blood-2015-02-628354

Published: 2015

Includes: Supplemental data

Journal Articles

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

Soranobu Ninomiya, Neeharika Narala, Leslie Huye, Shigeki Yagyu, Barbara Savoldo, Gianpietro Dotti, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Carlos A. Ramos

Blood (2015) 125 (25): 3905–3916.

https://doi.org/10.1182/blood-2015-01-621474

Published: 2015

Includes: Supplemental data

Journal Articles

T Cells Expressing CD19-Specific Chimeric Antigen Receptors Are Inhibited By Indoleamine 2,3-Dioxygenase in Tumors

Soranobu Ninomiya, MD PhD, Leslie E Huye, PhD, Barbara Savoldo, MD PhD, Gianpietro Dotti, MD, Helen E. Heslop, MD, Malcolm K. Brenner, MD PhD, Cliona M Rooney, PhD, Carlos A. Ramos, MD

Blood (2014) 124 (21): 2434.

https://doi.org/10.1182/blood.V124.21.2434.2434

Published: 2014

NARROW

Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma

Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)

Novel Immunotherapeutic Approaches for Hodgkin Lymphoma

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies

Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity

Safety of Multiple Doses of CAR T Cells

Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I/IIa Trial

Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

T Cells Expressing CD19-Specific Chimeric Antigen Receptors Are Inhibited By Indoleamine 2,3-Dioxygenase in Tumors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only